SynthioLabs

Executive Summary

SynthioLabs is a Boston-based biotechnology company founded in 2024 that leverages artificial intelligence and synthetic biology to design and engineer novel biologic therapeutics, including antibodies and enzymes with enhanced properties. Its integrated platform aims to overcome traditional limitations in biologic drug development by rapidly optimizing protein candidates for improved efficacy, stability, and manufacturability. The company operates at the intersection of AI-driven protein design and synthetic biology, targeting indications in oncology, immunology, and rare diseases. While still in the platform stage with no disclosed pipeline, SynthioLabs recently graduated from Y Combinator's biotech cohort, signaling strong early validation. The company is privately held and has not publicly disclosed funding rounds or valuation. Given its innovative approach and early-stage status, SynthioLabs represents a high-risk, high-reward opportunity in the emerging AI-enabled biologics space. Near-term success hinges on securing meaningful partnerships and advancing its platform through preclinical validation.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026First Major Pharma Partnership30% success
• Q2 2027Publication of Proof-of-Concept Data70% success